# Innate Pharma Reports €96.8 Million in Cash and Sets IPH4502 Data for November 18

> Innate Pharma ended September 2026 with €96.8 million in cash and financial assets, funded partly by Sobi's $75 million upfront.

- Published: 2026-11-05T06:42:06+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-05/innate-pharma-cash-position-iph4502-data
- Source: [Business Wire](https://www.businesswire.com/news/home/20261104506906/en/)

## Key takeaways

- Innate Pharma held €96.8 million in cash, cash equivalents and financial assets as of September 30, 2026.
- Phase 1 dose-escalation data for the Nectin-4 ADC IPH4502 will be presented at ENA 2026 on November 18, 2026.
- First patient dosing in the Phase 3 TELLOMAK-3 trial of lacutamab is expected in the first quarter of 2027.
- Chief Financial Officer Frédéric Lombard will step down on December 31, 2026.

Innate Pharma reported €96.8 million in cash, cash equivalents and financial assets as of September 30, 2026, alongside its financial update for the nine months ended September 30, 2026. The Marseille-based clinical-stage biotechnology company develops immunotherapies for cancer and is listed on Euronext Paris and Nasdaq. Business Wire [published](https://www.businesswire.com/news/home/20261104506906/en/) the update on November 5, 2026.

## Innate Pharma's Cash and IPH4502 Timeline

The €96.8 million figure includes short-term investments of €20.6 million and non-current financial instruments of €6.0 million. It also reflects the $75 million upfront payment from the closing of the Sobi transaction and gross proceeds from a €30 million private placement of ordinary shares in August 2026. Financial liabilities stood at €16.2 million as of September 30, 2026, and revenues for the first nine months of 2026 were €3.4 million, against €2.3 million a year earlier. The company said its anticipated cash horizon runs until the end of the first quarter of 2028.

"As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma.

Enrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types. Phase 1 dose-escalation data for IPH4502, a Nectin-4 exatecan ADC, will be presented as a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on November 18, 2026. Innate Pharma will host a hybrid event on IPH4502 the same day at 4:00 pm GMT, with in-person attendance in London and a live webcast.

Lacutamab is developed in collaboration with [Sobi](https://akta.pro/company-profiles/0002w1f/sobi), which reported higher-than-expected third-quarter 2026 profit and raised its full-year 2026 revenue forecast, according to Dagens industri. Innate Pharma is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, with first patient dosing expected in the first quarter of 2027. The study includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.

## Earlier Steps Toward the Lacutamab Study

On September 16, 2026, the Innate Pharma and Sobi partnership became effective after antitrust waiting periods expired, triggering the $75 million upfront payment, Stock Titan reported. The closing initiated the TELLOMAK-3 Phase 3 trial, with the first patient expected in the first quarter of 2027. On October 27, 2026, [AstraZeneca](https://akta.pro/company-profiles/000026p/astrazeneca) updated the expected readout of the PACIFIC-9 Phase 3 trial to the first half of 2027 from the second half of 2026, Stock Titan reported. The event-driven study evaluates durvalumab with monalizumab or oleclumab in unresectable Stage III NSCLC and has completed enrollment.

## Innate Pharma's Next Dates

Innate Pharma plans an FDA filing in the second half of 2027 for accelerated approval in Sézary syndrome based on existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway. Frédéric Lombard will step down as chief financial officer on December 31, 2026, and the company has begun a search for his replacement. The balance available under its April 2023 at-the-market sales agreement remained at $75 million as of September 30, 2026.

## Companies in this story

- Innate Pharma · website: https://www.innate-pharma.com
- [Sobi company profile](https://akta.pro/company-profiles/0002w1f/sobi) · website: https://sobi-uk.co.uk
- [AstraZeneca company profile](https://akta.pro/company-profiles/000026p/astrazeneca) · website: https://www.astrazeneca.com

---
News for Agent · https://newsforagent.com/llms.txt